Vandria’s VNA-318 enters clinical trials for treating age-related diseases
Vandria - 18-Dec-2024Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
Join the club for FREE to access the whole archive and other member benefits.
Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
Long-term follow-up data and post-hoc analyses fuel optimism for treating mitochondrial diseases
Phase 2 trial on sonlicromanol to test its ability in improving patient's symptoms & quality of life
Chronic inflammation and fibrosis further damage the heart health
New research from Texas A&M develops nanoflowers to restore cellular energy
Boosting fat loss and preserving muscle with cutting-edge mitochondrial therapy
New funding propels innovative mitophagy-inducing lead compound into clinical trials targeting Alzheimer’s and Parkinson’s
Company is developing therapies for Alzheimer's, Parkinson's, and Rett syndrome
Research underscores potential to revolutionise approach to healthy ageing
Research aims to extend lifespan and unlock new levels of human health
The discovery may improve inflammation treatment and anti-ageing interventions
It reduced blood sugar spikes and overall levels in healthy individuals
Making small changes to your lifestyle can have a significant impact on health
This discovery paves the way for potential anti-ageing therapies
Company's drug targets the root cause of diseases like Duchenne and COPD
Mitophagy-boosting drug candidate VNA-318 preps for clinical trials
Potential therapeutic approach for mitochondrial and other genetic diseases
Mitochondria targeting could lead to new treatments for age-related diseases
The test could identify drugs that reverse or slow down DNA damage and disease
Selectively inhibits problematic free radicals - potential breakthrough in treatment of chronic diseases & ageing
Explained the production and mechanisms of Urolithin A, and trial results of Timeline's Mitopure
Mitochondria dysfunction is linked to several ageing-related diseases, including neurodegeneration, so a big potential market
Targeting and eliminating mutated mtDNA by subjecting it to autophagy with rapamycin been successful
If successful in humans it would improve the outcome of many age-related diseases
Initially targeting ischemia-reperfusion injury, TMT has potential to treat multiple age-related diseases